Georgia vs Saudi Arabia: Share of E. coli infections resistant to cephalosporins
Georgia
46.5%
in 2022
Saudi Arabia
52.8%
in 2022
Georgia rank
18th
Saudi Arabia rank
15th
Share of E. coli infections resistant to cephalosporins over time
- Georgia
- Saudi Arabia
How they compare
Saudi Arabia currently reports 52.8% against 46.5% in Georgia, a difference of 6.3%.
That makes Saudi Arabia's figure about 1.1 times Georgia's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Saudi Arabia ahead.
Georgia ranks 18th and Saudi Arabia ranks 15th of 46 countries.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Georgia | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 53.1% | 54.3% | 1.2% | Saudi Arabia |
| 2020s | 41.8% | 54.7% | 12.9% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Georgia or Saudi Arabia?
- Saudi Arabia, at 52.8% against 46.5% in Georgia as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Georgia and Saudi Arabia?
- 6.3%, with Saudi Arabia ahead.
- How many years of comparable data are there for Georgia and Saudi Arabia?
- 6 years are reported by both, from 2017 to 2022.
- How do Georgia and Saudi Arabia rank globally for share of e. coli infections resistant to cephalosporins?
- Georgia ranks 18th and Saudi Arabia ranks 15th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).